CJC-1295 (WITH DAC) 5mg

CJC-1295 with DAC – 5 mg

Long-Acting GHRH Analog – Lyophilized Peptide for Research Use

CJC-1295 with DAC (Drug Affinity Complex) is a modified analog of Growth Hormone–Releasing Hormone (GHRH) developed for laboratory research involving growth hormone (GH) regulatory pathways.

The addition of the Drug Affinity Complex (DAC) extends the peptide’s half-life by facilitating reversible binding to circulating proteins, resulting in prolonged activity in experimental models. This extended-duration profile makes CJC-1295 with DAC a subject of interest in studies examining sustained GH signaling and hypothalamic–pituitary axis modulation.

In research settings, CJC-1295 with DAC is sometimes evaluated independently or alongside other growth hormone secretagogues to investigate coordinated GH release dynamics under controlled laboratory conditions.

This product is supplied as a high-purity lyophilized peptide intended strictly for research applications.

Product Specifications

• Peptide Name: CJC-1295 with DAC
• Purity: >98%
• Form: Lyophilized powder
• Quantity: 5 mg per vial
• Storage Conditions:
• Store at -20°C (-4°F) prior to reconstitution
• After reconstitution, refrigerate at 2–8°C (36–46°F)
• Use within 30 days of reconstitution
• Use Classification: Research use only

Areas of Laboratory Investigation

CJC-1295 with DAC may be incorporated into controlled research models involving:

• Sustained growth hormone (GH) release analysis
• GHRH receptor signaling pathway studies
• Hypothalamic–pituitary axis regulation research
• Long-acting peptide pharmacokinetic investigations
• Hormonal feedback loop and endocrine system modeling

Regulatory & Safety Notice

This compound is intended strictly for laboratory research purposes.
It is not approved for human consumption, clinical use, therapeutic treatment, or diagnostic procedures.
This material is not intended to diagnose, treat, cure, or prevent any disease.